Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Ocular Therapeutix (OCUL) over the last 13 years, with Q4 2025 value amounting to $449.4 million.

  • Ocular Therapeutix's Cash from Financing Activities rose 985736.76% to $449.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $561.7 million, marking a year-over-year increase of 6913.7%. This contributed to the annual value of $561.7 million for FY2025, which is 6913.7% up from last year.
  • Per Ocular Therapeutix's latest filing, its Cash from Financing Activities stood at $449.4 million for Q4 2025, which was up 985736.76% from $10.4 million recorded in Q3 2025.
  • In the past 5 years, Ocular Therapeutix's Cash from Financing Activities registered a high of $449.4 million during Q4 2025, and its lowest value of -$1.2 million during Q1 2021.
  • Moreover, its 5-year median value for Cash from Financing Activities was $3.4 million (2021), whereas its average is $53.4 million.
  • As far as peak fluctuations go, Ocular Therapeutix's Cash from Financing Activities crashed by 10906.54% in 2021, and later skyrocketed by 41172435.9% in 2024.
  • Over the past 5 years, Ocular Therapeutix's Cash from Financing Activities (Quarter) stood at $667000.0 in 2021, then crashed by 31.33% to $458000.0 in 2022, then soared by 23517.9% to $108.2 million in 2023, then crashed by 95.83% to $4.5 million in 2024, then skyrocketed by 9857.37% to $449.4 million in 2025.
  • Its last three reported values are $449.4 million in Q4 2025, $10.4 million for Q3 2025, and $97.8 million during Q2 2025.